welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Investigation Of Factors Affecting Hand Functions in Nonambulatory Patients With Duchenne Muscular Dystrophy
study id #: NCT03521271
condition: Duchenne Muscular Dystrophy
The aim of this study, determining the factors affecting the hand functions of children with Duchenne Muscular Dystrophy who have lost their independent ambulatory ability and determining the effects on the overall upper extremity performance and quality of life of the determined factors.
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: April 5, 2017
estimated completion: January 26, 2018
size / enrollment: 23
Duchenne Muscular Dystrophy (DMD) is the most common neuromuscular disease seen in childhood. DMD is an X linked recessive disorder. DMD is characterized by complete or partial (<3%) deficiency of the cell membrane protein dystrophin.
Dystrophin deficiency results in a permanent deterioration of muscle fibers. This leads to a progressive decrease in muscle strength and functional abilities. The precise mechanism of how the defect of dystrophin leads to degeneration of muscle fibers remains uncertain, but cytoskeletal deterioration, sarcolemmal instability and abnormal calcium homeostasis are thought to play a role in this degeneration.
These patients have symptoms such as limb proximals and progressive muscle weakness in the trunk, gait abnormalities, Gower's sign, various degrees of restriction in daily living activities, and frequent falls. The majority of patients have elevated serum creatine kinase or elevated liver transaminases and less frequently language or general developmental retardation.
Walking ability of this children begins to deteriorate between the ages of 3-6. These patients are generally dependent on wheelchair aged 10-12 years. The loss of walking is the milestone in terms of the progression of the disease. The use of electric wheelchairs limits arm functions such as lengthening and lifting during the late phase of the illness (when the ambulance has been lost and the ambulance is being continued with the wheelchair).
Patients with DMD have an average life span of 30 years with spinal surgery and ventilation support. They spend most of their lives dependent on the wheelchair and need functional use of the upper limbs to maintain the best possible level of independence in their daily life activities throughout their lifetimes.
Although muscle weakness in the proximal limbs is the first finding of the disease, the influence of upper extremity functions gives symptoms after 8 years of age and has a great influence on the level of independence of DMD patients in life since this process. For this reason, rehabilitation approaches for the protection of upper extremity functions from the early period of the disease are of great importance.Effective interventions are necessary to achieve this goal and these variables must be considered when making clinical decisions.
Patients with adult DMD have been shown to be able to perform important functional activities with limited distal motor function in the late phase of disease, but tend to lose these capacities as muscle strength decreases. For this reason, determining the factors (grip strength, thumb opposition, upper extremity joint range of motion, upper extremity muscle strength, etc.) that may affect hand functions, which is an important component in maintaining upper extremity functioning, and how these factors are related to the general functions of the upper extremity it is crucial that this disease leads to physiotherapy rehabilitation programs to be implemented.
- Brooke Upper Extremity Functional Classification (1-6) [ Time Frame: 2 minutes ]
Children's functional levels were assessed with Brooke Upper Extremity Functional Classification (BUEFS) and children with a BUEFS score between 1-5 were included in the study.
Starting with arms at sides, can abduct arms in a full circle until they touch above head Can raise arms above head only by flexing elbow or using accesory muscles
Cannot raise arms above head but can raise a glass of water to mouth (using both hands if necessary)
Can raise hands to mouth but cannot raise a glass of water to mouth
Cannot raise hand to mouth but can use hands to hold pen or pick up pennies from table
Cannot raise hands to mouth and has no useful function of hands
- Passive joint range of motion [ Time Frame: 10 minutes ]
Passive range of motions were assessed with goniometer and recorded limitations.
- Upper extremity muscle strength [ Time Frame: 20 minutes ]
Hand held dynamometer
- Thumb opposition [ Time Frame: 2 minutes ]
Thumb opposition was assessed by Kapandji score (1-10). Score Location achieved
Radial side of the proximal phalanx of the 2nd phalanx
Radial side of the middle phalanx of the 2nd phalanx
Tip of the 2nd phalanx
Tip of the 3th phalanx
Tip of the 4th phalanx
Tip of the 5th phalanx
Distal interphalangeal joint crease of the 5th phalanx
Proximal interphalangeal joint crease of the 5th phalanx
Metacarpophalangeal joint crease of the 5th phalanx
Distal palmar crease
- Lateral, tripod, two-point pinch strength [ Time Frame: 3 minutes ]
- Performance of the upper extremity [ Time Frame: 15 minutes ]
Performance of the Upper Limb (PUL) (0-74) is including three dimension:
Shoulder dimension (0-16)
Elbow dimension (0-34)
Distal dimension (0-24)
- Hand function [ Time Frame: 3 minutes ]
- Activity limitations [ Time Frame: 3 minutes ]
- Gross grip strength [ Time Frame: 2 minutes ]
- Quality of life assessment of children (0-100) [ Time Frame: 5 minutes ]
- Quality of life assessment of parents (0-100) [ Time Frame: 5 minutes ]
• Having a Duchenne Muscular Dystrophy diagnosis by a practicing physician,
• Between the ages of 8-16 years,
• Having lost ambulation ability,
• Brooke Upper Extremity Functional Classification (1-5)
• To have motivation and co-operation with physiotherapist for evaluations to be made
• To maintain the capacity of independent ambulance,
• Having cooperative disorder or serious mental disorder,
• Any spinal and / or upper extremity injuries and / or surgery in the last 6 months,
• Having any systemic disease other than DMD,
• Not volunteering to participate in the study
Clinical Intramuscular Gene Transfer Trial of rAAVrh74.MCK.Micro-Dystrophin to Patients With Duchenne Muscular Dystr...The proposed phase I clinical trial is a...
Corticosteroids for the treatment of Duchenne muscular dystrophyBackground:Duchenne muscular dystrophy (...
Safety Study of Flavocoxid in Duchenne Muscular DystrophyObjective of this study is to evaluate s...
For Many Boys With Duchenne Muscular Dystrophy, Bright Hope Lies Just Beyond ReachLucas was 5 before his parents, Bill and...
The Treatment of Duchenne Muscular Dystrophy: Equipoise, Fidelity and Standardshttps://www.youtube.com/watch?v=ji7Z23qH...
Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystroph...The proposed clinical trial is an outgro...
Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and CanadaDuchenne/Becker muscular dystrophy (DBMD...
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrop...Catabasis Pharmaceuticals, Inc., a clini...
Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access programSince the 1970s, the FDA has helped to f...